--(www.USEquityNews.com)-- 01/10/2008 - Medical business industry alert provided by U.S. Equity News. Medspas of America, Inc. (OTC: MEDP), www.medspasofamerica.com, announced recently that it has signed an agreement with Essential Wholesale to manufacture Natural Renu's product lines recently acquired from 2M Innovations. Essential Wholesale, www.essentialwholesale.com, and its partner company Essential Labs, both located in a suburb of Portland, Oregon, is an FDA Registered company manufacturing under the highest standards of quality control, in compliance with current Good Manufacturing Practices (cGMP). Essential Wholesale provides custom manufacturing and private label business for numerous customized natural skin care products all over the world.
Boston Scientific Corporation (NYSE: BSX) recently announced that it has completed the sale of its Cardiac Surgery and Vascular Surgery businesses to the Getinge Group of Sweden for $750 million in cash. The sale follows the definitive agreement announced on November 5, 2007. The Company expects to record after-tax charges of approximately $240 million in connection with the transaction. These charges will be recorded during the fourth quarter of 2007 and the first quarter of 2008.
At the JPMorgan 26th Annual Health Care Conference in San Francisco, Sciele Pharma, Inc. (NASDAQ: SCRX), recently announced that it will be launching during the first quarter of 2008 its new Sular(R) formulation, which was recently approved by the Federal Food & Drug Administration (FDA) in four dosage strengths: 8.5-milligram, 17-milligram and 25.5-milligram and 34-milligram dosages. In addition, the Company also plans to launch five new products in 2008: 120-milligram and 40-milligram fenofibrate doses for treatment of mixed dyslipidemia; Prandin(R) (repaglinide) for type II diabetes, and, upon FDA approval, PrandiMet(R) (repaglinide/metformin) also for type II diabetes; a head lice asphyxiation product upon FDA approval; and a new Women's Health product. Sciele also reaffirmed the Company's full-year guidance for both 2007 and 2008.
Reckitt Benckiser Group plc (RB.L) and Adams Respiratory Therapeutics, Inc. (NASDAQ: ARXT) announced recently that they have received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) relating to the previously announced tender offer to purchase all of the outstanding shares of common stock of Adams. Reckitt Benckiser initiated, through its wholly owned subsidiary Twickenham Inc., a cash tender offer on December 21, 2007, to purchase all outstanding shares of common stock of Adams for US$60.00 per share. The tender offer will expire at 12:00 midnight, New York City time, on January 23, 2008, unless extended in accordance with the Merger Agreement entered into between Reckitt Benckiser, Twickenham and Adams and the applicable rules and regulations of the U.S. Securities and Exchange Commission (SEC).
About U.S. Equity News
U.S. Equity News provides information, resources and news services for investors of small-cap, micro-cap and emerging companies. U.S. Equity News distributes RSS news feeds and a free subscription-based newsletter available through its website at www.usequitynews.com.
U.S. Equity News is a financial news distribution service by Equity Solutions, Inc. (www.equityirsolutions.com) that provides a platform for public companies to disseminate important news to key Wall Street interest such as shareholders and new investors. Equity Solutions, Inc. can assist by providing an effective increase in the awareness of a public company's news, development and corporate story through its proprietary network and its financial portal. U.S. Equity News and its affiliates charge each client cash for news distribution and may take an equity position in the companies mentioned herein, please visit the disclaimer at www.USEquityNews.com.
